摘要
目的:对阿洛西林钠组(A组)与羧苄西林钠(B组)治疗儿童支气管肺炎的药物经济学分析,为临床提供用药参考方案。方法:采用回顾性研究,分析A组与B组治疗儿童支气管肺炎的方案进行最小成本分析。结果:两组治疗儿童支气管肺炎的总有效率分别为97.06%和95.65%,效果差异无显著性(x2=0.627P>0.05);两组治疗成本分别为3013.88元和3813.67元,有显著性的差异(t=2.17P<0.05)。结论:阿洛西林钠治疗儿童支气管肺炎比羧苄西林钠经济,符合药物经济学原则。
Objective： Pharmacoeconomics analysis was used to help clinic drug admistration in treating Children＇s Bronchopneumonia. Methods： Retrospective study was used to analyze the cost-minimization. Results： These two drugs were efficient（Effective rate is 97.06% and 95.65%） and there was no significant difference （x^2 = 0.627 P 〉 0.05）. The total cost of two drugs were 3 013.88 yuan and 3 813.67 yuan and there was a significant difference （t = 2.17 P 〈 0.05）. Conclusions： It was economic to take azlocillin sodium than taking carbenicillin sodium.
出处
《抗感染药学》
2007年第1期19-21,共3页
Anti-infection Pharmacy
关键词
阿洛西林钠
羧苄西林钠
支气管肺炎
最小成本分析
Azlocillin sodium
carbenicillin sodium
bronchopneumonia
cost-minimization analysis
